Recent advances in the unique clinicopathologic entity of lymphoblastic lym
phoma (and its variants) are discussed in this article, which details the n
atural history, molecular biology, prognosis, and outcome with various chem
otherapy regimens. Improved outcome with the newer intensive chemotherapy r
egimens and the role of modalities such as autologous intensification, allo
geneic bone marrow transplant, and radiotherapy are discussed.